Fig. 1

Serum cfnucleosome modifications in IPF. Discrimination of five Nu.Q™ assays for untreated IPF (n = 23), treated IPF (n = 27), and healthy subjects (HS) (n = 27). Treatment is pirfenidone (n = 18) and nintedanib (n = 9). Nu.Q™ assays were performed from serum samples. Significant separation between the untreated IPF and healthy controls was achieved with pre-processed ELISA data from the five cfnucleosome biomarkers. Significant discrimination between the treated and untreated patients was achieved from the two cfnucleosome biomarkers. p values were determined by the Mann-Whitney U test. Box plots indicate the median and 25th and 75th percentiles. Whiskers indicate the 10 and 90% percentiles and dot values falling outside the 10th and 90th percentiles. IPF idiopathic pulmonary fibrosis, OD optical density